Product Specification
| Host |
Mouse |
| Antigen |
CD19 |
| Synonyms |
B-lymphocyte antigen CD19; LE-CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12 |
| Location |
Cell membrane |
| Accession |
P15391 |
| Clone Number |
S-R503-2 |
| Antibody Type |
Mouse mAb |
| Isotype |
IgG1 |
| Application |
FCM |
| Reactivity |
Hu |
| Positive Sample |
human PBMC |
| Purification |
Protein G |
| Concentration |
0.05mg/ml |
| Conjugation |
Alexa Fluor® 488 |
| Physical Appearance |
Liquid |
| Storage Buffer |
PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage |
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied. |
Dilution
| application |
dilution |
species |
| FCM |
5 μl per million cells in 100μl volume |
Hu |
Background
CD19 is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, predominantly expressed on B lymphocytes, making it a significant marker for B cell development and function. It plays a crucial role in B cell activation, signal transduction, and growth regulation. CD19 is involved in the B cell receptor (BCR) signaling pathway, enhancing B cell activation thresholds and proliferation. In the context of disease, CD19 is highly expressed in most B cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B cell lymphomas, making it a promising target for immunotherapy. The CD19 molecule is also implicated in autoimmune and immunodeficiency disorders, with mutations in CD19 associated with severe immunodeficiency syndromes characterized by reduced antibody production.
